“Making NSCLC management personal: An interview in 4 case studies” will take a look back in time through the career of a Consultant Clinical Oncologist and how four case studies helped shape their management of NSCLC.

During an interactive interview conducted by Dr. Lim, Dr. John Conibear will share his reasons why those case studies helped to inform his clinical management and the learnings he took away to better support future patient care.

We hope you will find the symposium both educational and thought provoking and look forward to seeing you there.
UK Prescribing Information

Alecensa® (alectinib)

**150 mg hard capsules**

Each hard capsule contains alectinib hydrochloride equivalent to 150 mg alectinib. Refer to Summary of Product Characteristics (SPC) prior to use of Alecensa.

Indications:

Alecensa is indicated for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC following prior platinum based chemotherapy.

Contraindications: A pretreatment ALK assay is necessary for the selection of ALK-positive NSCLC patients. ALK-positive NSCLC status should be established prior to initiation of Alecensa therapy. The recommended dose of Alecensa is 150 mg, taken twice daily with food (total daily dose of 300 mg). Patients with underlying severe hepatic impairment should receive a starting dose of 75 mg twice daily with food (total daily dose of 150 mg). Do not administer Alecensa to patients with prior rituximab treatment.

Precautions:

**Infusion-reactions;** Immune-related myocarditis; Immune-related pancreatitis; Immune-related meningoencephalitis; signs and symptoms of endocrinopathies. Thyroid function should be monitored.

**Side effects**

Immune-related pneumonitis; Monitor for pulmonary symptoms indicative of pneumonitis. Immediately interrupt in patients diagnosed with ILD/pneumonitis and permanently discontinue if symptomatic. Potential causes of ILD/pneumonitis have been reported, refer to SPC. Bradycardia; Hypersensitivity to alectinib or to any of the excipients.

**Adverse reactions**:

Very Common: asthenia, urinary tract infections, anemia, diarrhea, vomiting, constipation, nausea, increased alanine transaminase, increased aspartate transaminase, increased bilirubin, increased blood creatine phosphokinase, thrombocytopenia, hypersensitivity, photosensitivity.

Common: acute kidney injury, dysgeusia, stomatitis, vision disorders, urinary tract infections, nausea, vomiting, diarrhea, constipation, nausea, myalgia, increased blood creatine phosphokinase, increased total bilirubin, decreased hemoglobin, dehydration.

**Photosensitivity:** Patients should be advised to avoid exposure to strong sunlight or to sunlamps, to wear sunscreen and to use protective clothing.

**Drug Interactions:** Avoid grapefruit juice, grapefruit and Seville oranges. Monitor patients if sodium for an adult.

**Pregnancy and Lactation:** Alecensa may cause foetal harm during pregnancy. Patients of child-bearing potential receiving Alecensa should be advised to report a pregnancy while taking Alecensa or during the 3 months following the last dose. Patients of child-bearing potential receiving Alecensa should be advised to use a reliable method of contraception. Effectiveness of oral contraceptives may be reduced.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

**Adverse events should be reported.**

**Reporting forms and information can be found at:**

UK Prescribing Information

**Legal Category:**

POM

**Presentation and Basic NHS Cost:** 1200 mg / 20ml.

**Marketing Authorisation Number:** EU/1/17/1220/001

**Supplied by:** Roche Products Limited, & Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

Alecensa® is a registered trade mark

RXUKMED00227(3)

Date of Preparation: May 2018

---

**Tecentriq**

1,200 mg concentrate for solution for infusion

Each 20ml vial of concentrate contains 1,200 mg alectinib. Refer to Summary of Product Characteristics (SPC) prior to use of Tecentriq.

**Indications:** As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum containing chemotherapy, or who are not eligible for or have not responded to platinum-containing chemotherapy. Patients with EGF activating mutations or ALK positive tumour mutations should also have received crizotinib, and be receiving crizotinib at the time of diagnosis. Patients with previously untreated UC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test. The recommended dose of Tecentriq is 1,200 mg administered intravenously every three weeks. The initial dose administered should be adjusted if necessary based on individual safety and effectiveness. It must not be administered as an intravenous bolus. In the first 3 months of treatment. Thereafter monitoring should be performed periodically, with more frequent monitoring in patients who develop autoimmune or pneumonitis. Treatment should be withheld and resumed at a reduced dose, or permanently discontinued, refer to SPC. Severe myalgia and creatine phosphokinase (CPK) elevation: Patients should be advised to report any unexplained muscle pain, tenderness, or weakness. CPK levels should be assessed every 2 weeks for the first 3 months of treatment. If a CPK elevation ≥ 5x the upper limit of normal is detected in patients reporting symptoms. Based on the severity of the CPK elevation, Alecensa will be withheld, then resumed at the same dose or dose reduced, refer to SPC. Bradycardia: Heart rate and blood pressure should be monitored as clinically indicated. Evaluate concomitant medicinal products known to cause bradycardia as anti-arrhythmic agents, anti-hypertensive medicinal products if patients experience symptomatic bradycardia or life-threatening events. Symptomatic bradycardia can be managed with treatment interruption, dose reduction. If life-threatening, permanently discontinue if no contributing concomitant medicinal product is identified or if signs and symptoms of CPK elevation, refer to SPC. Hyperkalaemia: CPK elevation, refers to SPC. Hypersensitivity to atezolizumab or to any of the excipients.

**Drug Interactions:**

Drug Interactions: Avoid grapefruit juice, grapefruit and Seville oranges. Monitor if sodium for an adult.

**Adverse reactions:**

Very Common: decreased appetite, dysphagia, cough, nausea, vomiting, diarrhoea, dyspepsia, fatigue, dyspnoea, cough, blood pressure should be monitored as clinically indicated. Evaluate concomitant medicinal products known to cause bradycardia as anti-arrhythmic agents, anti-hypertensive medicinal products if patients experience symptomatic bradycardia or life-threatening events. Symptomatic bradycardia can be managed with treatment interruption, dose reduction. If life-threatening, permanently discontinue if no contributing concomitant medicinal product is identified or if signs and symptoms of CPK elevation, refer to SPC. Hyperkalaemia: CPK elevation, refers to SPC. Hypersensitivity to atezolizumab or to any of the excipients.

Drug Interactions: Avoid grapefruit juice, grapefruit and Seville oranges. Monitor if symptoms. Based on the severity of the CPK elevation, Alecensa will be withheld, then resumed at the same dose or dose reduced, refer to SPC. Bradycardia: Heart rate and blood pressure should be monitored as clinically indicated. Evaluate concomitant medicinal products known to cause bradycardia as anti-arrhythmic agents, anti-hypertensive medicinal products if patients experience symptomatic bradycardia or life-threatening events. Symptomatic bradycardia can be managed with treatment interruption, dose reduction. If life-threatening, permanently discontinue if no contributing concomitant medicinal product is identified or if signs and symptoms of CPK elevation, refer to SPC. Hyperkalaemia: CPK elevation, refers to SPC. Hypersensitivity to atezolizumab or to any of the excipients.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

**Adverse events should be reported.**

**Reporting forms and information can be found at:**

UK Prescribing Information

**Legal Category:**

POM

Presentation and Basic NHS Cost:** 1200 mg / 20ml.

**Marketing Authorisation Number:** EU/1/17/1220/001

**Supplied by:** Roche Products Limited, & Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom

Tecentriq® is a registered trade mark

RXUKMED00228(3)

Date of Preparation: June 2018

---

**Tecentriq**

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

**Adverse events should also be reported to Roche Products Ltd.** Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

**Roche Ireland:** irland.drug_surveillance_centre@roche.com, 01 4690700.

HPRA Pharmacovigilance: medsafety@hpра.ie, 01 6764791. Alecensa legal classification Roche Ireland - Product subject to medical prescription which may not be renewed (A).

---

**Nivolumab**

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

**Adverse events should also be reported to Roche Products Ltd.** Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

**Roche Ireland:** irland.drug_surveillance_centre@roche.com, 01 4690700.

HPRA Pharmacovigilance: medsafety@hpра.ie, 01 6764791. Alecensa legal classification Roche Ireland - Product subject to medical prescription which may not be renewed (A).